© Getty Images

AARDEX Group named founding member of CancerX initiative

By Isabel Cameron

Adherence specialist AARDEX Group has been announced as a founding member of the CancerX initiative, which aims to bring diverse stakeholders together to drive innovation and improve follow up for cancer patients.

© Getty Images

Roche licenses drug to target cancer DNA damage response

By Jonathan Smith

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQ’s lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

© Getty Inages

Charm Therapeutics gains investment from NVentures to develop therapeutics for cancer

By Charm Therapeutics gains investment from NVentures for cancer therapeutics

Charm Therapeutics has announced investment from NVentures – NVIDIA’s venture investment arm. This represents a major milestone for Charm and means it will be able to deliver more on its research and development (R&D) activities for novel oncology...


Follow us


Featured Suppliers